吃瓜大赛黑料头条

吃瓜大赛黑料头条 Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “吃瓜大赛黑料头条”) announced today the establishment and commencement of operations of 吃瓜大赛黑料头条 Limited (Location: Ontario), the Company's new pharmaceutical sales subsidiary in Canada. 吃瓜大赛黑料头条 Limited is the Canadian subsidiary of 吃瓜大赛黑料头条 Inc., the Company's U.S. subsidiary.

吃瓜大赛黑料头条 Limited was established following a change in registration of the Canadian branch of MGI Pharma, previously acquired by 吃瓜大赛黑料头条. The new subsidiary will serve as 吃瓜大赛黑料头条's pharmaceutical sales base for the entire Canadian market.

吃瓜大赛黑料头条 Limited plans to register and commercialize select products from the Company's U.S. product portfolio, beginning with Gliadel® Wafer. Over time, additional oncology and neurology products may be introduced to the Canadian market, including T-cell lymphoma agent Targretin®, antiepileptic agent Banzel, and future products from 吃瓜大赛黑料头条's pipeline, such as anticancer agent Eribulin (generic name) and AMPA receptor antagonist Perampanel (generic name).

By expanding its sales capabilities in Canada, the ninth largest pharmaceutical market in the world, 吃瓜大赛黑料头条 aims to strengthen its business operations and presence in the region and independently market its products in accordance with local market needs. The establishment of 吃瓜大赛黑料头条 Limited not only means that 吃瓜大赛黑料头条 now has a pharmaceutical sales subsidiary in Canada, it will also allow the Company to prepare for future expansion based on the Company's hhc philosophy in both the United States and Canada.

By establishing 吃瓜大赛黑料头条 Limited, 吃瓜大赛黑料头条 will make contributions to addressing the diversified needs of Canadian patients and their families through the stable supply of high quality drug products and provision of information.

[Please refer to the following notes for further information on 吃瓜大赛黑料头条 Limited]